| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 6, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesityPL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025Received €2.0M ($2.3M) upfrontAchieved €5.5M ($6.5
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common stock (or pre-funded warrants in lieu thereof).
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical modelsClinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially synergistic approach to weight managementPL7737 IND-enabling toxicology underway, with an IND submission and clinical trial initiation planned for the first half of 2026; clinical data expected in the second half of 2026PRINCETON, N.J., Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB:PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentat
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -
CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q
Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)